The anticancer activity of antisense microRNA (fRNA) in combination with the lectin from Bacillus subtilis B-7025

J Pharm Pharmacol. 2018 Jun;70(6):732-739. doi: 10.1111/jphp.12898. Epub 2018 Mar 9.

Abstract

Objectives: Many adenocarcinomas have the ability to capture from an extracellular matrix the oligonucleotides and nanoparticles by pinocytosis, when the non-cancerous cells are not capable to capture the oligonucleotides and small liposomes. This provides selective accumulation of proposed protected oligonucleotides (fRNA) in cancer cells and also provides the absence toxicity in the fRNA.

Methods: For the immunotherapy, we used immunotropic 70 kDa lectin Bacillus subtilis B-7025. In vivo experiments were carried out in C57BL line mice in Lewis lung carcinoma. The cytotoxic activity, lymphocytes and macrophages were determined in vitro using the MTT assay.

Key findings: Animal survival rate in groups receiving either the fRNA or lectine was 70 and 40%, respectively.

Conclusions: Combined use of fRNA and lectine has the advantage compared with the use of these drugs in monotherapy, as the anticancer efficacy of the scheme is much higher, which is manifested in the primary tumour node and metastasis inhibition.

Keywords: HPLC; Lewis lung carcinoma; anticancer; antisense microRNA; lectin Bacillus subtilis B-7025.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bacillus subtilis / chemistry*
  • Carcinoma, Lewis Lung / drug therapy*
  • Carcinoma, Lewis Lung / genetics*
  • Carcinoma, Lewis Lung / pathology
  • Lectins / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / genetics*
  • MicroRNAs / therapeutic use*
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Metastasis / prevention & control
  • Survival Rate

Substances

  • Lectins
  • MicroRNAs